Back
Halozyme Therapeutics Stock Price Chart
Sponsored
HALO
Sponsored
Hedge fund manager warns about the market ahead
Free book prepares you for the coming uncertainty in the stock market
Buy
60
HALO
Halozyme Therapeutics
Last Price:
59.35
Seasonality Move:
10.79%
7 Day Trial
ALL ACCESS PASS
$
7
32,481% Growth? Meet Mode Mobile's "EarnPhone"
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.- The current trend is moderately bearish and HALO is experiencing slight selling pressure.
Halozyme Therapeutics Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 60.99 | Buy |
20-day SMA: | 61.77 | Buy |
50-day SMA: | 57.93 | Buy |
200-day SMA: | 45.18 | Buy |
8-day EMA: | 61.61 | Buy |
20-day EMA: | 60.88 | Buy |
50-day EMA: | 57.95 | Buy |
200-day EMA: | 48.51 | Buy |
Halozyme Therapeutics Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 1.05 | Buy |
Relative Strength Index (14 RSI): | 59.06 | Buy |
Chaikin Money Flow: | -96167 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (59.62 - 63.1) | Buy |
Bollinger Bands (100): | (45.2 - 59.3) | Buy |
Halozyme Therapeutics Technical Analysis
Sep 5 | Sep 6 | Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | |
---|---|---|---|---|---|---|---|---|---|---|
Sep | ||||||||||
05 | 06 | 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 62.31 while HALO 8-day simple moving average is 60.99, which is a Buy signal.
- The stock price of HALO is 62.31 while Halozyme Therapeutics 20-day SMA is 61.77, which makes it a Buy.
- Halozyme Therapeutics 50-day simple moving average is 57.93 while HALO share price is 62.31, making it a Buy technically.
- HALO stock price is 62.31 and Halozyme Therapeutics 200-day simple moving average is 45.18, creating a Buy signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
60
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a Buy
The current Halozyme Therapeutics [HALO] share price is $62.31. The Score for HALO is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
7.89B
Price in USD:
62.31
Share Volume:
1.18M
Halozyme Therapeutics 52-Week Range
52-Week High:
65.53
52-Week Low:
32.83
Buy
60
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?
The Halozyme Therapeutics stock price is 62.31 USD today. -
Will HALO stock go up or go down?
Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Halozyme Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 62.31 while HALO 8-day exponential moving average is 61.61, which is a Buy signal.
- The stock price of HALO is 62.31 while Halozyme Therapeutics 20-day EMA is 60.88, which makes it a Buy.
- Halozyme Therapeutics 50-day exponential moving average is 57.95 while HALO share price is 62.31, making it a Buy technically.
- HALO stock price is 62.31 and Halozyme Therapeutics 200-day simple moving average is 48.51, creating a Buy signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.30 per share, an increase next quarter of $0.25 per share, an increase this year of $1.19 per share, and an increase next year of $0.84 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
- HALO Moving Average Covergence Divergence (MACD) indicator is 1.05, suggesting Halozyme Therapeutics is a Buy
- Halozyme Therapeutics Relative Strength Index (RSI) is 59.06, which suggest Halozyme Therapeutics is overbought
- The Bollinger Bands (25) for Halozyme Therapeutics is (59.62 - 63.1), which suggest Halozyme Therapeutics is a Buy
- The Bollinger Bands (100) for Halozyme Therapeutics is (45.2 - 59.3), which suggest Halozyme Therapeutics is a Buy
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.